Immunogen (IMGN) – Business Wire
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
-
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
-
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
-
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
-
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
-
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Canaccord Genuity 43rd Annual Growth Conference
-
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates
-
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
-
ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
-
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
-
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
-
ImmunoGen Announces Proposed Public Offering of Common Stock
-
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
-
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
-
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
-
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Reports Recent Progress and 2022 Financial Results
-
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
-
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
-
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
-
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
-
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
-
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
-
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
Back to IMGN Stock Lookup
